Phagenesis closes €7m series B funding round
This article was originally published in Clinica
Dysphagia specialist Phagenesis has closed a €7m ($9.3m) series B funding round. The Manchester, UK company aims to accelerate the development of an innovative device that aids swallowing through electrical stimulation. The device, which “delivers a precisely sequenced and calibrated electrical signal to the pharynx of the dysphagic patient”, has demonstrated safety and efficacy in helping the patient to swallow. The investment is led by life science fund Inventages, with the participation of existing shareholders. Phagenesis is “ideally-placed” to address a “critical unmet need in a very large market”, said Inventages founder Gunnar Weikert. Ashok Dhanrajgir, senior partner at Inventages, will join Phagenesis as board director.
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.